WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :

Download Article: Click Here

Search

Track Your Article

Abstract

INVASIVE MUCORMYCOSIS (A BLACK FUNGUS); EMERGING CHALLENGE & COMPLICATION IN POST COVID-19 PATIENT

Jyoti Anand Gosavi*, Trunali Tukaram Prabhu and Anuja Arvind Sawant

Abstract

Even as the world is grappling with the continuing effects of the COVID-19 pandemic, a new health issue appears to be quickly reaching the potential of an outbreak in India & other country is Mucormycosis. Mucormycosis (previously called zygomycosis) is a rare but serious angio-invasive life-threatening infection caused by a group of fungi called mucormycetes. associated with high morbidity and mortality. Rhizopus species are the most causative organisms of this group & species that are most frequently isolated from patients include Mucor, Cunninghamella, Apophysomyces, Lichtheimia (formerly Absidia), Saksenaea, Rhizo mucor. Inhaling fungal spores from the air can affect the lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. Clinical presentation is classified according to the organ involvement. It can be rhino-orbital cerebral, pulmonary, cutaneous, gastrointestinal, or disseminated. Mucormycosis is well known to infect patients with diabetes mellitus, malignancy, chemotherapy, and other immunocompromised conditions. Mucormycosis, aspergillosis and invasive candidiasis, have been reported in patients with severe COVID-19 or those recovering patients with COVID-19. current diagnosis is dependent on culture and histopathological examination is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized test.Treatment of mucormycosis is Amphotericin B (AmB) is the firstline drug of choice; subsequently, posaconazole and isavuconazole are prescribed reliant on reversal of underlying predisposing factors, surgical debridement of infected tissues and appropriate antifungal therapy & treatment of COVID-19 largely remains systemic steroids and other immunomodulators that add to the risk of invasive fungal infection. Diagnosis and aggressive treatment of mucormycosis, the mortality rate of the disease remains high.

Keywords: Rhizopus oryzae, COVID-19, Amphotericin-B, Diabetes mellitus, antifungal therapy.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More